Literature DB >> 1348345

Tamoxifen-associated hepatocellular damage and agranulocytosis.

C K Ching, P G Smith, R G Long.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1348345     DOI： 10.1016/0140-6736(92)90991-b

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Tamoxifen in the prevention of breast cancer. Are the risks likely to outweigh the benefits?

Authors:  M O'Brien; T J Powles
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

2.  Phase I study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue.

Authors:  H Pujol; J Girault; P Rouanet; S Fournier; J Grenier; J Simony; J B Fourtillan; J L Pujol
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 3.  A risk-benefit assessment of tamoxifen therapy.

Authors:  W H Catherino; V C Jordan
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606

4.  Agranulocytosis Induced by Tamoxifen in a Breast Cancer Patient.

Authors:  Hugo Herrscher; Julie Leblanc; Thierry Petit
Journal:  Breast Care (Basel)       Date:  2019-06-20       Impact factor: 2.860
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.